Amendment to Schedule 13D Filing for TEMPEST THERAPEUTICS, INC.

This filing is an amendment to a previous Schedule 13D filing related to the common stock of Tempest Therapeutics, Inc. The amendment details transactions occurring on March 24, 2026, where Factor Biosciences Inc. acquired 231,482 shares of Common Stock and warrants to purchase 462,964 shares of Common Stock. Matthew Angel, the majority stockholder and Chairman of Factor, exercises voting and investment power over these shares. Factor purchased these securities for an aggregate price of $500,001.12. The filing also references a prior transaction on February 3, 2026, involving the acquisition of 4,837,070 shares by Erigen LLC. As of March 24, 2026, the Reporting Person, Matthew Angel, is deemed to beneficially own 37.4% of the Issuer's outstanding Common Stock, totaling 5,531,516 shares, with sole voting and dispositive power. The filing includes details on the Asset Purchase Agreement, a Lock-up Agreement, an Employment Agreement for Dr. Angel, a Security Purchase Agreement, a Registration Rights Agreement, and forms of warrants.